FDA Approves Shorter 2-Hour Ocrevus Infusion!

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

If you are currently being treated with Ocrevus, ask your doctor about the shorter 2-hour Ocrevus infusion! If you would like more information on the new FDA approved 2-hour Ocrevus infusion please see below:

Click here for the official press release for the FDA Approval of the 2-hour Ocrevus infusion time!